83.22
price up icon2.41%   1.96
after-market アフターアワーズ: 83.00 -0.22 -0.26%
loading
前日終値:
$81.26
開ける:
$81.76
24時間の取引高:
527.39K
Relative Volume:
0.49
時価総額:
$2.39B
収益:
$55.23M
当期純損益:
$-164.08M
株価収益率:
-12.16
EPS:
-6.8461
ネットキャッシュフロー:
$-208.68M
1週間 パフォーマンス:
+10.84%
1か月 パフォーマンス:
+13.61%
6か月 パフォーマンス:
+46.30%
1年 パフォーマンス:
+12,950%
1日の値動き範囲:
Value
$81.39
$83.76
1週間の範囲:
Value
$74.79
$83.76
52週間の値動き範囲:
Value
$0.57
$83.76

Nektar Therapeutics Stock (NKTR) Company Profile

Name
名前
Nektar Therapeutics
Name
セクター
Healthcare (1112)
Name
電話
(415) 482-5300
Name
住所
455 MISSION BAY BOULEVARD SOUTH, SAN FRANCISCO, CA
Name
職員
63
Name
Twitter
@nektarnews
Name
次回の収益日
2026-03-12
Name
最新のSEC提出書
Name
NKTR's Discussions on Twitter

Compare NKTR vs VRTX, REGN, ARGX, ALNY, ONC

株式 価格 時価総額 収益 当期純利益 現金流量 EPS
NKTR icon
NKTR
Nektar Therapeutics
83.22 2.33B 55.23M -164.08M -208.68M -6.8461
VRTX icon
VRTX
Vertex Pharmaceuticals Inc
441.70 113.01B 12.07B 3.95B 3.19B 15.33
REGN icon
REGN
Regeneron Pharmaceuticals Inc
753.93 79.87B 14.34B 4.50B 3.77B 41.56
ARGX icon
ARGX
Argen X Se Adr
840.87 51.51B 4.16B 1.29B 734.26M 19.58
ALNY icon
ALNY
Alnylam Pharmaceuticals Inc
333.39 45.29B 3.71B 313.75M 465.38M 2.2571
ONC icon
ONC
Beone Medicines Ltd Adr
319.94 34.41B 5.36B 287.73M 924.18M 2.5229

Nektar Therapeutics Stock (NKTR) Upgrades & Downgrades

日付 アクション アナリスト 評価の変更
2026-03-24 開始されました Wedbush Neutral
2026-03-17 開始されました TD Cowen Buy
2026-02-10 アップグレード William Blair Mkt Perform → Outperform
2025-11-26 開始されました Citigroup Buy
2025-06-24 繰り返されました BTIG Research Buy
2025-06-24 繰り返されました H.C. Wainwright Buy
2025-04-11 アップグレード Jefferies Hold → Buy
2025-03-14 アップグレード Oppenheimer Perform → Outperform
2025-01-08 開始されました B. Riley Securities Buy
2024-12-10 開始されました H.C. Wainwright Buy
2024-11-04 開始されました Piper Sandler Overweight
2024-09-30 再開されました BTIG Research Buy
2024-06-28 開始されました Rodman & Renshaw Buy
2023-11-20 再開されました JP Morgan Underweight
2023-11-09 アップグレード TD Cowen Market Perform → Outperform
2023-05-10 アップグレード Jefferies Underperform → Hold
2023-02-24 ダウングレード Jefferies Hold → Underperform
2022-08-08 ダウングレード JP Morgan Neutral → Underweight
2022-05-31 再開されました Jefferies Hold
2022-04-18 ダウングレード Goldman Neutral → Sell
2022-03-15 ダウングレード Cowen Outperform → Market Perform
2022-03-15 ダウングレード Mizuho Buy → Neutral
2022-03-14 ダウングレード BTIG Research Buy → Neutral
2022-03-14 ダウングレード BofA Securities Neutral → Underperform
2022-03-14 ダウングレード Stifel Buy → Hold
2022-03-14 ダウングレード William Blair Outperform → Mkt Perform
2022-03-09 アップグレード Oppenheimer Perform → Outperform
2021-11-08 アップグレード The Benchmark Company Hold → Buy
2021-09-10 開始されました BofA Securities Neutral
2021-06-28 アップグレード Stifel Hold → Buy
2021-05-18 再開されました Goldman Neutral
2021-02-22 ダウングレード The Benchmark Company Buy → Hold
2021-01-06 開始されました Stifel Hold
2020-09-14 開始されました JP Morgan Neutral
2020-06-10 ダウングレード CFRA Hold → Sell
2020-05-12 繰り返されました H.C. Wainwright Neutral
2020-04-22 開始されました The Benchmark Company Buy
2020-03-30 アップグレード Goldman Sell → Neutral
2020-03-04 開始されました Barclays Overweight
2020-02-03 アップグレード Mizuho Neutral → Buy
2019-10-24 開始されました Oppenheimer Perform
2019-10-08 ダウングレード Goldman Buy → Sell
2019-08-09 ダウングレード JP Morgan Overweight → Neutral
2019-08-09 ダウングレード Jefferies Buy → Hold
2019-08-09 ダウングレード Mizuho Buy → Neutral
2019-03-15 開始されました SVB Leerink Mkt Perform
2018-12-13 開始されました Goldman Buy
2018-06-11 ダウングレード H.C. Wainwright Buy → Neutral
2018-06-04 繰り返されました H.C. Wainwright Buy
2018-04-20 開始されました Seaport Global Securities Buy
2018-04-13 再開されました Piper Jaffray Overweight
2018-04-06 繰り返されました Mizuho Buy
2018-04-02 再開されました H.C. Wainwright Buy
すべてを表示

Nektar Therapeutics (NKTR) 最新ニュース

pulisher
03:20 AM

Nektar Therapeutics (NKTR) Shareholders Who Lost Money Have Opportunity to Lead Securities Fraud Lawsuit - PR Newswire

03:20 AM
pulisher
11:21 AM

NKTR Faruqi & Faruqi, LLP Reminds Nektar Therapeutics (NKTR) Investors of Securities Class Action Deadline on May 5, 2026 - marketscreener.com

11:21 AM
pulisher
11:04 AM

NKTR INVESTOR ALERT: Bronstein, Gewirtz and Grossman, LLC Announces that Nektar Therapeutics Stockholders with Substantial Losses Have Opportunity to Lead Class Action Lawsuit! - ACCESS Newswire

11:04 AM
pulisher
09:03 AM

Nektar Therapeutics Upcoming AA Data Prediction: Why I Think It Will Be Positive - Seeking Alpha

09:03 AM
pulisher
09:00 AM

NKTR Investor Alert: Nektar Therapeutics Securities Fraud LawsuitInvestors With Losses May Seek to Lead the Class Action After Allegedly Failing Clinical Enrollment Standards: Levi & Korsinsky - PR Newswire

09:00 AM
pulisher
Apr 14, 2026

Pomerantz Law Firm Announces the Filing of a Class Action Against Nektar Therapeutics, Inc. and Certain Officers – NKTR - ChartMill

Apr 14, 2026
pulisher
Apr 14, 2026

Bronstein, Gewirtz & Grossman LLC Urges Nektar Therapeutics - GlobeNewswire

Apr 14, 2026
pulisher
Apr 14, 2026

NEKTAR THERAPEUTICS (NKTR) DEADLINE ALERT Bernstein Liebhard LLP Reminds Nektar Therapeutics Investors of Upcoming Deadline - TMX Newsfile

Apr 14, 2026
pulisher
Apr 14, 2026

NKTR Shareholder Alert: Investors With Losses May Seek to Lead the Class Action in Nektar Therapeutics Securities Lawsuit — The Gross Law Firm - Morningstar

Apr 14, 2026
pulisher
Apr 14, 2026

SHAREHOLDER ALERT Bernstein Liebhard LLP Announces A - GlobeNewswire

Apr 14, 2026
pulisher
Apr 14, 2026

Lead Plaintiff Deadlines in Shareholder Class Action - GlobeNewswire

Apr 14, 2026
pulisher
Apr 13, 2026

NKTR Investor Alert: Nektar Therapeutics Securities Fraud - GlobeNewswire

Apr 13, 2026
pulisher
Apr 13, 2026

Portnoy Law Firm Announces Class Action on Behalf of Nektar Therapeutics, Inc. Investors - GlobeNewswire

Apr 13, 2026
pulisher
Apr 13, 2026

Nektar Therapeutics stock hits 52-week high at 78.95 USD By Investing.com - Investing.com Canada

Apr 13, 2026
pulisher
Apr 13, 2026

Nektar Therapeutics stock hits 52-week high at 78.95 USD - Investing.com

Apr 13, 2026
pulisher
Apr 13, 2026

Nektar Therapeutics stock (US6354171056): Is its immunology pipeline strong enough to unlock new ups - AD HOC NEWS

Apr 13, 2026
pulisher
Apr 13, 2026

NKTR Investors Have Opportunity to Lead Nektar Therapeutics Securities Fraud Lawsuit with the Schall Law Firm - PR Newswire

Apr 13, 2026
pulisher
Apr 12, 2026

ROSEN, A LEADING AND RANKED FIRM, Encourages Nektar Therapeutics Investors to Secure Counsel ... - Bluefield Daily Telegraph

Apr 12, 2026
pulisher
Apr 12, 2026

ROSEN, A LEADING AND RANKED FIRM, Encourages Nektar Therapeutics Investors to Secure Counsel Before Important Deadline in Securities Class Action - GlobeNewswire Inc.

Apr 12, 2026
pulisher
Apr 12, 2026

Certain Restricted Stock Unit of Nektar Therapeutics are subject to a Lock-Up Agreement Ending on 13-APR-2026. - marketscreener.com

Apr 12, 2026
pulisher
Apr 12, 2026

Certain Stock Options of Nektar Therapeutics are subject to a Lock-Up Agreement Ending on 13-APR-2026. - marketscreener.com

Apr 12, 2026
pulisher
Apr 12, 2026

Certain Common Stock of Nektar Therapeutics are subject to a Lock-Up Agreement Ending on 13-APR-2026. - marketscreener.com

Apr 12, 2026
pulisher
Apr 11, 2026

Nektar Therapeutics (HAM:ITH0) Stock Price & 30 Year Financial Data - GuruFocus

Apr 11, 2026
pulisher
Apr 10, 2026

NKTR Shareholder Alert: Nektar Therapeutics Securities Class Action Lawsuit Investors With ... - Bluefield Daily Telegraph

Apr 10, 2026
pulisher
Apr 10, 2026

NKTR Shareholder Alert: Nektar Therapeutics Securities - GlobeNewswire

Apr 10, 2026
pulisher
Apr 10, 2026

NKTR UPCOMING DEADLINE: Faruqi & Faruqi, LLP Reminds Nektar Therapeutics (NKTR) Investors of Securities Class Action Deadline on May 5, 2026 - Morningstar

Apr 10, 2026
pulisher
Apr 10, 2026

Nektar Therapeutics stock: What investors need to know in immunotherapy's next wave - AD HOC NEWS

Apr 10, 2026
pulisher
Apr 10, 2026

Press releases provided by CNW - Techaeris

Apr 10, 2026
pulisher
Apr 10, 2026

A Look At Nektar Therapeutics (NKTR) Valuation After Rezpegaldesleukin Trial Progress And Litigation Concerns - Sahm

Apr 10, 2026
pulisher
Apr 09, 2026

NKTR Investors Have Opportunity to Lead Nektar Therapeutics Secu - GuruFocus

Apr 09, 2026
pulisher
Apr 09, 2026

NKTR Investors Have Opportunity to Lead Nektar Therapeutics Securities Fraud Lawsuit - PR Newswire

Apr 09, 2026
pulisher
Apr 09, 2026

Nektar Therapeutics (NKTR) Shareholders Who Lost Money Have Oppo - GuruFocus

Apr 09, 2026
pulisher
Apr 09, 2026

Bragar Eagel & Squire, P.C. Announces that a Class Action - GlobeNewswire

Apr 09, 2026
pulisher
Apr 09, 2026

ROSEN, GLOBAL INVESTOR COUNSEL, Encourages Nektar - GlobeNewswire

Apr 09, 2026
pulisher
Apr 09, 2026

Lawsuit filed for Investors who lost money with shares of Nektar Therapeutics (NASDAQ: NKTR) - openPR.com

Apr 09, 2026
pulisher
Apr 09, 2026

Pomerantz Law Firm Announces the Filing of a Class Action Against Nektar Therapeutics, Inc. and Certain OfficersNKTR - PR Newswire

Apr 09, 2026
pulisher
Apr 09, 2026

NKTR INVESTOR ALERT: Bronstein, Gewirtz and Grossman, LLC Reminds Shareholders of Nektar Therapeutics to Contact the Firm Today! - ACCESS Newswire

Apr 09, 2026
pulisher
Apr 09, 2026

NEKTAR THERAPEUTICS (NKTR) DEADLINE ALERT Bernstein - GlobeNewswire

Apr 09, 2026
pulisher
Apr 08, 2026

Deadline Alert: Nektar Therapeutics (NKTR) Shareholders Who - GlobeNewswire

Apr 08, 2026
pulisher
Apr 08, 2026

NKTR Shareholder Alert: Investors With Losses May Seek to Lead the Class Action in Nektar Therapeutics Securities Lawsuit -- The Gross Law Firm - Sahm

Apr 08, 2026
pulisher
Apr 07, 2026

Pomerantz Law Firm Announces the Filing of a Class Action Against Nektar Therapeutics, Inc. and Certain Officers – NKTR - GlobeNewswire Inc.

Apr 07, 2026
pulisher
Apr 07, 2026

NEKTAR THERAPEUTICS (NKTR) SHAREHOLDER ALERT Bernstein Liebhard LLP Reminds Nektar Therapeutics Investors of Upcoming Deadline - TMX Newsfile

Apr 07, 2026
pulisher
Apr 07, 2026

Nektar (NKTR) Poised for Potential Upside with Upcoming Data Rel - GuruFocus

Apr 07, 2026
pulisher
Apr 07, 2026

Citi Maintains Nektar Therapeutics(NKTR.US) With Buy Rating, Maintains Target Price $123 - 富途牛牛

Apr 07, 2026
pulisher
Apr 07, 2026

Nektar Goes Silent: What's Behind The Quiet Period? - RTTNews

Apr 07, 2026
pulisher
Apr 07, 2026

Citi Adds Nektar Therapeutics (NKTR) to 30-Day Upside Catalyst Watch List - StreetInsider

Apr 07, 2026
pulisher
Apr 07, 2026

Wall Street Analysts Are Bullish on Top Healthcare Picks - theglobeandmail.com

Apr 07, 2026
pulisher
Apr 06, 2026

Holzer & Holzer Reminds Investors of Lead Plaintiff Deadlines in Shareholder Lawsuits - National Today

Apr 06, 2026
pulisher
Apr 06, 2026

Rosen Law Firm Encourages Nektar Therapeutics Investors to Secure Counsel Before Deadline - National Today

Apr 06, 2026
pulisher
Apr 06, 2026

ROSEN, RECOGNIZED INVESTOR COUNSEL, Encourages Nektar Therapeutics Investors to Secure Counsel ... - Bluefield Daily Telegraph

Apr 06, 2026
pulisher
Apr 06, 2026

ROSEN, RECOGNIZED INVESTOR COUNSEL, Encourages Nektar - GlobeNewswire

Apr 06, 2026

Nektar Therapeutics (NKTR) 財務データ

収益

loading

当期純利益

loading

現金流量

loading

EPS

loading
$54.26
price up icon 2.69%
$48.70
price down icon 0.25%
$99.47
price up icon 1.08%
$152.54
price up icon 3.76%
$146.74
price down icon 4.34%
ONC ONC
$319.94
price up icon 3.21%
大文字化:     |  ボリューム (24 時間):